Protein kinase inhibitors

Worldwide Anaplastic Lymphoma Kinase ALK Inhibitors Industry to 2026 - Featuring Astellas Pharma, AstraZeneca ad Pfizer Among Others

Retrieved on: 
Thursday, April 22, 2021
Chemical compounds, Protein kinase inhibitors, Tyrosine kinase receptors, Branches of biology, Clinical medicine, Anaplastic lymphoma kinase, ALK inhibitor, Lymphoma, Piperidines, ALK, Crizotinib, T-cell lymphoma

b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector.

Key Points: 
  • b'DUBLIN, April 22, 2021 /PRNewswire/ -- The "Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector.
  • The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market.
  • The global anaplastic lymphoma kinase inhibitor market is going to witness high growth rate and is expected to double in next 5 years.
  • In addition to this, several emerging ALK inhibitors along with their clinical trials are also provided in the report.\n'

U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial Cancer

Retrieved on: 
Tuesday, April 13, 2021
Oncology, Health, FDA, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Breast cancer, Cancer, Infectious causes of cancer, Metastatic breast cancer, Clinical medicine, Bladder cancer, Health, Protein kinase inhibitors, Neuvenge, CDK inhibitor

The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study.

Key Points: 
  • The accelerated approval was based on data from the international Phase 2, single-arm TROPHY study.
  • An estimated 83,000 Americans will be diagnosed with bladder cancer in 2021, and almost 90% of those diagnoses will be UC.
  • Trodelvy is also being developed as an investigational treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Global C5 Complement Inhibitor Soliris Ultomiris Market Clinical Trial Research Outlook 2026

Retrieved on: 
Sunday, April 18, 2021
Orphan drugs, Drugs, Immunosuppressants, Eculizumab, Health care, Ravulizumab, C5, Protein kinase inhibitors, Medicinal chemistry

b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.

Key Points: 
  • b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.
  • Various new C5 complement targeting candidates are under clinical stage of development, which will further broaden the therapeutic potential of this segment and takes C5 complement inhibitor market to the next level.
  • Therefore, C5 complement market has potential to transform the future market of rare diseases and intense growth is expected in this sector.
  • It is believed that the C5 complement inhibitors will overtake a major portion of the orphan drugs segment in near future.\n'

Global C5 Complement Inhibitor Soliris Ultomiris Market Clinical Trial Research Outlook 2026

Retrieved on: 
Sunday, April 18, 2021
Orphan drugs, Drugs, Immunosuppressants, Eculizumab, Health care, Ravulizumab, C5, Protein kinase inhibitors, Medicinal chemistry

b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.

Key Points: 
  • b'"Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026" Report Highlights:\nGlobal C5 Complement Inhibitors Drug Market Opportunity: > USD 15 Billion\nGlobal C5 Complement Inhibitors Drug Market Absolute Growth: 65% (2017 -2020)\nGlobal C5 Complement Inhibitors Drug Market Growth In 2020: 21% (> USD 5 Billion)\nCommercially Available C5 Complement Inhibitors Drugs: 3 (Soliris, Ultomiris & Elizaria)\nSoliris (Eculizumab) Sales In 2020: > USD 3 Billion\nThe C5 complement inhibitors are emerging as a novel therapeutic approach for the management of rare disease and this segment is expected to hold a major share in the future orphan drug market.
  • Various new C5 complement targeting candidates are under clinical stage of development, which will further broaden the therapeutic potential of this segment and takes C5 complement inhibitor market to the next level.
  • Therefore, C5 complement market has potential to transform the future market of rare diseases and intense growth is expected in this sector.
  • It is believed that the C5 complement inhibitors will overtake a major portion of the orphan drugs segment in near future.\n'

US Breast Cancer Drug Therapeutics Market USD 20 Billion By 2026

Retrieved on: 
Monday, April 12, 2021
Breast cancer, Health, Cancer, Drugs, Protein kinase inhibitors, CDK inhibitor, Breast cancer research stamp

b'"US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:\nUS Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026\nUS Breast Cancer clinical Trials: 350 Drugs in Pipeline\nMarketed Breast Cancer Drugs Dosage, Patent & Pricing\nThe US pharmaceutical market is known to have the biggest breakthroughs in the entire industry.

Key Points: 
  • b'"US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:\nUS Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026\nUS Breast Cancer clinical Trials: 350 Drugs in Pipeline\nMarketed Breast Cancer Drugs Dosage, Patent & Pricing\nThe US pharmaceutical market is known to have the biggest breakthroughs in the entire industry.
  • In a very efficient mechanism, the US breast cancer therapeutics market has created a momentum which is now believed to be the strong backbone of the global breast cancer therapeutics market.
  • In addition, an overall increase in the rate of breast cancer patients in the country is also believed to be one of the primary reasons for having such efficient clinical pipeline for the patients which was never observed by the researchers few decades ago.\nAs per "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" findings, it is predicted that the US breast cancer market will be leading the race of occupying and delivering maximum healthcare advantages to the patients suffering from different sub-types of breast cancer.
  • The profound identification as well as approval of different major therapeutic agents for the breast cancer patients as well as strong clinical background for breast cancer therapy market such as enhanced publications and research journals are believed to eventually incline the entire market as a major contributor to the global breast cancer therapy market.

US Breast Cancer Drug Therapeutics Market USD 20 Billion By 2026

Retrieved on: 
Monday, April 12, 2021
Breast cancer, Health, Cancer, Drugs, Protein kinase inhibitors, CDK inhibitor, Breast cancer research stamp

b'"US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:\nUS Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026\nUS Breast Cancer clinical Trials: 350 Drugs in Pipeline\nMarketed Breast Cancer Drugs Dosage, Patent & Pricing\nThe US pharmaceutical market is known to have the biggest breakthroughs in the entire industry.

Key Points: 
  • b'"US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights:\nUS Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026\nUS Breast Cancer clinical Trials: 350 Drugs in Pipeline\nMarketed Breast Cancer Drugs Dosage, Patent & Pricing\nThe US pharmaceutical market is known to have the biggest breakthroughs in the entire industry.
  • In a very efficient mechanism, the US breast cancer therapeutics market has created a momentum which is now believed to be the strong backbone of the global breast cancer therapeutics market.
  • In addition, an overall increase in the rate of breast cancer patients in the country is also believed to be one of the primary reasons for having such efficient clinical pipeline for the patients which was never observed by the researchers few decades ago.\nAs per "US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" findings, it is predicted that the US breast cancer market will be leading the race of occupying and delivering maximum healthcare advantages to the patients suffering from different sub-types of breast cancer.
  • The profound identification as well as approval of different major therapeutic agents for the breast cancer patients as well as strong clinical background for breast cancer therapy market such as enhanced publications and research journals are believed to eventually incline the entire market as a major contributor to the global breast cancer therapy market.

Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates

Retrieved on: 
Friday, April 9, 2021
Immune system, Clusters of differentiation, Branches of biology, Cancer immunotherapy, Checkpoint inhibitor, Colony stimulating factor 1 receptor, Immune checkpoint, Programmed cell death protein 1, Health care, Protein kinase inhibitors

For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.

Key Points: 
  • For MET/SRC/CSF1R inhibitor TPX-0022, the company will present preclinical data demonstrating potential utility in combination with immune checkpoint inhibitors.
  • With the new data, Turning Point is evaluating a potential additional combination study of TPX-0022 and an anti-PD-1 checkpoint inhibitor.
  • Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Turning Point Therapeutics drug candidates, the results, conduct, progress and timing of Turning Point Therapeutics pre-clinical studies and plans regarding future development activities.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update

Retrieved on: 
Thursday, April 8, 2021
Biotechnology, Pharmaceutical, Managed care, Oncology, General Health, Health, Clinical trials, Other Health, Clinical medicine, Cancer, Medicine, HER2/neu, Breast cancer, Protein kinase inhibitors, Pertuzumab, Triple-negative breast cancer, the Phase 1b Gedatolisib Clinical Trial, Gedatolisib, Celcuity

We are very encouraged by this preliminary data for gedatolisib from our ongoing Phase 1b trial in patients with breast cancer, said Brian Sullivan, CEO and Co-Founder of Celcuity.

Key Points: 
  • We are very encouraged by this preliminary data for gedatolisib from our ongoing Phase 1b trial in patients with breast cancer, said Brian Sullivan, CEO and Co-Founder of Celcuity.
  • Preliminary Phase 1b Data for Gedatolisib:
    The preliminary Phase 1b data set for the 103 patients enrolled utilized a January 11, 2021 data cut-off.
  • The B2151009 trial is a multicenter, open-label, on-going Phase 1b study in patients with ER+/HER2- metastatic breast cancer.
  • An on-going Phase 1b trial evaluating patients with ER+/HER2- metastatic breast cancer was initiated in 2016 and subsequently enrolled 138 patients.

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

Retrieved on: 
Thursday, April 8, 2021
Drugs, Clinical medicine, Cancer treatments, CD135, Chronic lymphocytic leukemia, Protein kinase inhibitors, Acute myeloid leukemia, Tumors of the hematopoietic and lymphoid tissues, Leukemia, Bruton's tyrosine kinase, Antineoplastic drugs, Phosphoinositide 3-kinase inhibitor

The Aptose management team also will be hosting 1x1 meetings during the event.

Key Points: 
  • The Aptose management team also will be hosting 1x1 meetings during the event.
  • Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology.
  • The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
  • The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).

FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

Retrieved on: 
Thursday, April 8, 2021
Oncology, Medical Supplies, Health, Hospitals, Pharmaceutical, Biotechnology, Chemical compounds, Cancer, Breast cancer, Clinical medicine, Breakthrough therapy, Protein kinase inhibitors, Metastatic breast cancer, Brain metastasis, Metástasis, Triple-negative breast cancer, CDK inhibitor

Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting.

Key Points: 
  • Prior to the FDA approval of Trodelvy, patients with previously treated metastatic TNBC had few treatment options in this high unmet-need setting.
  • Trodelvy is also being developed as an investigational treatment for metastatic urothelial cancer, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER 2-) metastatic breast cancer and metastatic non-small cell lung cancer.
  • TNBC is an aggressive type of breast cancer, accounting for approximately 15% of all breast cancers.
  • Additional efficacy measures included PFS for the full population (all patients with and without brain metastases) and overall survival (OS).